HUTCHMED Receives Conditional Approval for ORPATHYS® in Gastric Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Source: Newsfilter
- NDA Approval: HUTCHMED's ORPATHYS® (savolitinib) has received conditional approval from the China National Medical Products Administration for treating MET-amplified advanced gastric cancer patients, marking a significant advancement in precision medicine.
- Clinical Trial Results: In a pivotal Phase II registration study, ORPATHYS® achieved an objective response rate (ORR) of 32.3%, exceeding the pre-specified efficacy threshold, indicating its potential to significantly improve patient outcomes in MET-amplified gastric cancer.
- Market Demand: With MET amplification accounting for approximately 4-6% of gastric cancer patients and an estimated annual incidence of 18,000 in China, the approval of ORPATHYS® provides a new treatment option for this high-demand market, further solidifying HUTCHMED's market position.
- Strategic Partnership: HUTCHMED's collaboration with AstraZeneca will accelerate the commercialization of ORPATHYS®, expected to enhance its availability in the Chinese market and meet the growing needs of cancer patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HCM
Wall Street analysts forecast HCM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 11.650
Low
22.00
Averages
22.00
High
22.00
Current: 11.650
Low
22.00
Averages
22.00
High
22.00
About HCM
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HUTCHMED Receives Conditional Approval for ORPATHYS® in Gastric Cancer
- NDA Approval: HUTCHMED's ORPATHYS® (savolitinib) has received conditional approval from the China National Medical Products Administration for treating MET-amplified advanced gastric cancer patients, marking a significant advancement in precision medicine.
- Clinical Trial Results: In a pivotal Phase II registration study, ORPATHYS® achieved an objective response rate (ORR) of 32.3%, exceeding the pre-specified efficacy threshold, indicating its potential to significantly improve patient outcomes in MET-amplified gastric cancer.
- Market Demand: With MET amplification accounting for approximately 4-6% of gastric cancer patients and an estimated annual incidence of 18,000 in China, the approval of ORPATHYS® provides a new treatment option for this high-demand market, further solidifying HUTCHMED's market position.
- Strategic Partnership: HUTCHMED's collaboration with AstraZeneca will accelerate the commercialization of ORPATHYS®, expected to enhance its availability in the Chinese market and meet the growing needs of cancer patients.
See More
HUTCHMED to Announce Interim Results on July 30
- Interim Results Announcement: HUTCHMED will announce its interim results for the six months ended June 30, 2026, on July 30, 2026, at 7:00 am EDT, showcasing the company's latest advancements in the biopharmaceutical sector.
- Webcast Presentation: Management will host an English webcast at 8:00 am EDT on the same day, followed by a Q&A session, aimed at enhancing interaction with analysts and investors.
- Chinese Webcast Timing: The Chinese (Putonghua) webcast is scheduled for 8:30 am HKT on July 31, 2026, further broadening communication channels with Mandarin-speaking investors.
- Company Background: HUTCHMED is an innovative commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases, committed to bringing drug candidates from in-house discovery to patients worldwide.
See More
HUTCHMED's Fanregratinib Meets Primary Endpoint in Phase 2 Study
- Clinical Trial Success: HUTCHMED's Fanregratinib achieved a 42.5% objective response rate in the pivotal Phase 2 registrational study for intrahepatic cholangiocarcinoma, successfully meeting its primary endpoint and demonstrating potential in treating advanced patients.
- Drug Application Progress: The New Drug Application for Fanregratinib has been accepted for priority review by the Chinese National Medical Products Administration in December 2025, based on Phase 2 trial data, accelerating its path to commercialization.
- Safety Assessment: Among treated patients, 48.3% reported drug-related adverse events of Grade 3 or higher, primarily elevated liver enzymes and palmar-plantar erythrodysesthesia syndrome, indicating a safety profile consistent with known FGFR inhibitor mechanisms.
- Future Presentation Plans: The trial results will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 4, 2024, in Munich, Germany, which is expected to further enhance Fanregratinib's market visibility and clinical recognition.
See More
Fanregratinib Shows Promising Results in ICC Treatment
- Clinical Trial Results: Fanregratinib achieved an objective response rate of 42.5% in a pivotal Phase II registration study for advanced intrahepatic cholangiocarcinoma (ICC) patients with FGFR2 fusions/rearrangements, highlighting its potential as a new treatment option, particularly for those previously treated with chemotherapy.
- Survival Data: The study reported a median overall survival of 16.6 months with no treatment-related deaths, indicating significant clinical value in improving patient survival rates and the potential to reshape treatment paradigms in this challenging patient population.
- Safety Profile: While 48.3% of patients experienced drug-related adverse events of Grade 3 or higher, the treatment discontinuation rate was only 2.2%, demonstrating a favorable safety profile for Fanregratinib, making it suitable for broader clinical application.
- Regulatory Progress: The New Drug Application (NDA) for Fanregratinib has been accepted for priority review by the China National Medical Products Administration, marking a significant step towards its potential market launch in China and enhancing HUTCHMED's competitive position in the global biopharmaceutical landscape.
See More
HUTCHMED Reports Phase III Results for Sovleplenib in wAIHA
- Clinical Trial Success: HUTCHMED's Sovleplenib demonstrated a durable response rate of 66% in the Phase III ESLIM-02 study, significantly higher than the 15% in the placebo group, indicating strong efficacy in treating wAIHA and potentially enhancing market acceptance.
- Significant Market Potential: The market for wAIHA is projected to grow from $0.6 billion in 2025 to $0.93 billion by 2030, with a CAGR of 9.2%, providing a robust commercial foundation for Sovleplenib's market entry.
- Favorable Safety Profile: Sovleplenib exhibited a favorable safety profile, with 43% of patients experiencing grade 3 or higher treatment-emergent adverse events compared to 59% in the placebo group, indicating a competitive edge in safety.
- Rapid Response Time: The median time to response for Sovleplenib was 3.1 weeks, significantly shorter than the 6.3 weeks for placebo, with longer response duration, highlighting its potential advantages in clinical application and attracting investor interest.
See More
Sovleplenib Shows Promising Results in wAIHA Treatment
- Clinical Trial Results: The ESLIM-02 study demonstrated that sovleplenib achieved a durable response rate of 66% in 90 treated patients, significantly surpassing the 15% in the placebo group (p<0.0001), indicating its substantial potential in treating wAIHA.
- Safety Profile: Sovleplenib exhibited a favorable safety profile with grade ≥3 adverse events occurring in 43% of patients, lower than the 59% in the placebo group, and no treatment-related deaths or discontinuations reported, highlighting its viability for clinical use.
- Significant Treatment Effects: During the 24-week double-blind treatment period, sovleplenib significantly reduced the proportion of patients requiring rescue therapy (16% vs 54%, p=0.0001), with 50% of patients able to taper or discontinue glucocorticoids, thereby enhancing patient quality of life.
- Regulatory Progress: Sovleplenib has received priority review from the China National Medical Products Administration and accepted a New Drug Application in April 2026, marking significant regulatory advancements in the treatment landscape for wAIHA and indicating potential market opportunities ahead.
See More
HUTCHMED Receives Conditional Approval for ORPATHYS® in Gastric Cancer
- NDA Approval: HUTCHMED's ORPATHYS® (savolitinib) has received conditional approval from the China National Medical Products Administration for treating MET-amplified advanced gastric cancer patients, marking a significant advancement in precision medicine.
- Clinical Trial Results: In a pivotal Phase II registration study, ORPATHYS® achieved an objective response rate (ORR) of 32.3%, exceeding the pre-specified efficacy threshold, indicating its potential to significantly improve patient outcomes in MET-amplified gastric cancer.
- Market Demand: With MET amplification accounting for approximately 4-6% of gastric cancer patients and an estimated annual incidence of 18,000 in China, the approval of ORPATHYS® provides a new treatment option for this high-demand market, further solidifying HUTCHMED's market position.
- Strategic Partnership: HUTCHMED's collaboration with AstraZeneca will accelerate the commercialization of ORPATHYS®, expected to enhance its availability in the Chinese market and meet the growing needs of cancer patients.
See More
HUTCHMED to Announce Interim Results on July 30
- Interim Results Announcement: HUTCHMED will announce its interim results for the six months ended June 30, 2026, on July 30, 2026, at 7:00 am EDT, showcasing the company's latest advancements in the biopharmaceutical sector.
- Webcast Presentation: Management will host an English webcast at 8:00 am EDT on the same day, followed by a Q&A session, aimed at enhancing interaction with analysts and investors.
- Chinese Webcast Timing: The Chinese (Putonghua) webcast is scheduled for 8:30 am HKT on July 31, 2026, further broadening communication channels with Mandarin-speaking investors.
- Company Background: HUTCHMED is an innovative commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases, committed to bringing drug candidates from in-house discovery to patients worldwide.
See More
HUTCHMED's Fanregratinib Meets Primary Endpoint in Phase 2 Study
- Clinical Trial Success: HUTCHMED's Fanregratinib achieved a 42.5% objective response rate in the pivotal Phase 2 registrational study for intrahepatic cholangiocarcinoma, successfully meeting its primary endpoint and demonstrating potential in treating advanced patients.
- Drug Application Progress: The New Drug Application for Fanregratinib has been accepted for priority review by the Chinese National Medical Products Administration in December 2025, based on Phase 2 trial data, accelerating its path to commercialization.
- Safety Assessment: Among treated patients, 48.3% reported drug-related adverse events of Grade 3 or higher, primarily elevated liver enzymes and palmar-plantar erythrodysesthesia syndrome, indicating a safety profile consistent with known FGFR inhibitor mechanisms.
- Future Presentation Plans: The trial results will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 4, 2024, in Munich, Germany, which is expected to further enhance Fanregratinib's market visibility and clinical recognition.
See More
Fanregratinib Shows Promising Results in ICC Treatment
- Clinical Trial Results: Fanregratinib achieved an objective response rate of 42.5% in a pivotal Phase II registration study for advanced intrahepatic cholangiocarcinoma (ICC) patients with FGFR2 fusions/rearrangements, highlighting its potential as a new treatment option, particularly for those previously treated with chemotherapy.
- Survival Data: The study reported a median overall survival of 16.6 months with no treatment-related deaths, indicating significant clinical value in improving patient survival rates and the potential to reshape treatment paradigms in this challenging patient population.
- Safety Profile: While 48.3% of patients experienced drug-related adverse events of Grade 3 or higher, the treatment discontinuation rate was only 2.2%, demonstrating a favorable safety profile for Fanregratinib, making it suitable for broader clinical application.
- Regulatory Progress: The New Drug Application (NDA) for Fanregratinib has been accepted for priority review by the China National Medical Products Administration, marking a significant step towards its potential market launch in China and enhancing HUTCHMED's competitive position in the global biopharmaceutical landscape.
See More
HUTCHMED Reports Phase III Results for Sovleplenib in wAIHA
- Clinical Trial Success: HUTCHMED's Sovleplenib demonstrated a durable response rate of 66% in the Phase III ESLIM-02 study, significantly higher than the 15% in the placebo group, indicating strong efficacy in treating wAIHA and potentially enhancing market acceptance.
- Significant Market Potential: The market for wAIHA is projected to grow from $0.6 billion in 2025 to $0.93 billion by 2030, with a CAGR of 9.2%, providing a robust commercial foundation for Sovleplenib's market entry.
- Favorable Safety Profile: Sovleplenib exhibited a favorable safety profile, with 43% of patients experiencing grade 3 or higher treatment-emergent adverse events compared to 59% in the placebo group, indicating a competitive edge in safety.
- Rapid Response Time: The median time to response for Sovleplenib was 3.1 weeks, significantly shorter than the 6.3 weeks for placebo, with longer response duration, highlighting its potential advantages in clinical application and attracting investor interest.
See More
Sovleplenib Shows Promising Results in wAIHA Treatment
- Clinical Trial Results: The ESLIM-02 study demonstrated that sovleplenib achieved a durable response rate of 66% in 90 treated patients, significantly surpassing the 15% in the placebo group (p<0.0001), indicating its substantial potential in treating wAIHA.
- Safety Profile: Sovleplenib exhibited a favorable safety profile with grade ≥3 adverse events occurring in 43% of patients, lower than the 59% in the placebo group, and no treatment-related deaths or discontinuations reported, highlighting its viability for clinical use.
- Significant Treatment Effects: During the 24-week double-blind treatment period, sovleplenib significantly reduced the proportion of patients requiring rescue therapy (16% vs 54%, p=0.0001), with 50% of patients able to taper or discontinue glucocorticoids, thereby enhancing patient quality of life.
- Regulatory Progress: Sovleplenib has received priority review from the China National Medical Products Administration and accepted a New Drug Application in April 2026, marking significant regulatory advancements in the treatment landscape for wAIHA and indicating potential market opportunities ahead.
See More
